Sebastian Palmqvist

List of Publications by Year
in descending order

137	11,024	38738 50	34984 98
papers	citations	h-index	g-index

154	154	154	8364
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
2	Plasma P-tau181 in Alzheimerâ€™s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimerâ€™s dementia. Nature Medicine, 2020, 26, 379-386.	30.7	643
3	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	7.4	640
4	Earliest accumulation of Î²-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	12.8	596
5	Plasma Î²-amyloid in Alzheimerâ€™s disease and vascular disease. Scientific Reports, 2016, 6, 26801.	3.3	442
6	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.1	371
7	<scp>CSF</scp> AÎ²42/AÎ²40 and AÎ²42/AÎ²38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	3.7	329
8	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid Î²-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	9.0	300
9	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
10	Cerebrospinal fluid analysis detects cerebral amyloid-Î² accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	7.6	292
11	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.1	288
12	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Diseaseâ€“Related Î²-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	9.0	282
13	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 1683.	12.8	252
14	Prediction of future Alzheimerâ€™s disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	30.7	236
15	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	6.9	228
16	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	6.9	219
17	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
18	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.1	207

#	Article	IF	Citations
19	AÎ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	10.3	202
20	Plasma GFAP is an early marker of amyloid-Î² but not tau pathology in Alzheimerâ€™s disease. Brain, 2021, 144, 3505-3516.	7.6	198
21	Associations between tau, AÎ², and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.1	196
22	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	9.0	176
23	¹⁸Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	6.9	156
24	Longitudinal plasma p-tau217 is increased in early stages of Alzheimerâ€™s disease. Brain, 2020, 143, 3234-3241.	7.6	150
25	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. Brain, 2017, 140, 2286-2294.	7.6	149
26	Staging Î²-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	9.0	149
27	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
28	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	9.0	136
29	The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. Journal of Alzheimer's Disease, 2017, 59, 893-901.	2.6	133
30	Bloodâ€based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	6.9	122
31	Plasma biomarkers of Alzheimerâ€™s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	12.8	115
32	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.1	96
33	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	11.6	94
34	Soluble Pâ€tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	6.9	90
35	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	11.0	85
36	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85

#	Article	IF	Citations
37	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.1	83
38	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.1	80
39	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
40	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 76.	4.8	78
41	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	7.6	78
42	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimerâ€™s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS ONE, 2012, 7, e38639.	2.5	73
43	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
44	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. International Journal of Geriatric Psychiatry, 2009, 24, 1405-1412.	2.7	72
45	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma AÎ²42/AÎ²40 and pâ€tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.8	72
46	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	9.0	66
47	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	7.6	65
48	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	7.6	65
49	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.1	60
50	Tau PET correlates with different Alzheimerâ€™s diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	6.9	58
51	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	6.0	57
52	Greater tau load and reduced cortical thickness in APOE Îµ4-negative Alzheimerâ€™s disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	6.2	56
53	Assessing risk for preclinical Î²â€amyloid pathology with APOE, cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	2.4	49
54	Accurate risk estimation of Î²â€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.8	49

#	Article	IF	Citations
55	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral Î²-amyloidosis. Nature Communications, 2016, 7, 10918.	12.8	48
56	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cerebral Cortex, 2019, 29, 2173-2182.	2.9	39
57	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	12.8	36
58	Association between Subcortical Lesions and Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2011, 32, 417-423.	1.5	33
59	Cerebral inflammation is an underlying mechanism of early death in Alzheimerâ€™s disease: a 13-year cause-specific multivariate mortality study. Alzheimer's Research and Therapy, 2014, 6, 41.	6.2	33
60	Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. BMC Neurology, 2013, 13, 140.	1.8	31
61	Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2020, 75, 1191-1201.	2.6	31
62	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and AÎ² Pathology in Non-demented Individuals. Frontiers in Aging Neuroscience, 2017, 9, 306.	3.4	30
63	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.1	30
64	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 29.	6.2	29
65	Amyloid Network Topology Characterizes the Progression of Alzheimerâ€™s Disease During the Predementia Stages. Cerebral Cortex, 2018, 28, 340-349.	2.9	28
66	Î²-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	3.3	28
67	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
68	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that intersect with pathology, APOE Îµ4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	5.7	25
69	Testâ€retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.8	24
70	Association of Î²-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.1	22
71	Cerebral hypoperfusion is not associated with an increase in amyloid Î² pathology in middleâ€aged or elderly people. Alzheimer's and Dementia, 2018, 14, 54-61.	0.8	21
72	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimerâ€™s Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	1.3	21

#	Article	IF	Citations
73	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 113-122.	1.3	20
74	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. Current Alzheimer Research, 2012, 9, 257-266.	1.4	17
75	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimerâ€™s dementia in mild cognitive impairment patients. Alzheimer's Research and Therapy, 2022, 14, 46.	6.2	17
76	Association of CSF AÎ² ₃₈ Levels With Risk of Alzheimer Diseaseâ€“Related Decline. Neurology, 2022, 98, .	1.1	16
77	Effects of APOE Îµ4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	3.1	15
78	Cognitively normal women with Alzheimerâ€™s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer's Research and Therapy, 2019, 11, 109.	6.2	14
79	Derivation and utility of an AÎ²-PET pathology accumulation index to estimate AÎ² load. Neurology, 2020, 95, e2834-e2844.	1.1	14
80	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30.	6.2	14
81	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 439-446.	1.9	11
82	A quick test of cognitive speed can predict development of dementia in Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 15417.	3.3	11
83	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. NeuroImage: Clinical, 2020, 27, 102310.	2.7	10
84	Unburdening dementia â€“ a basic social process grounded theory based on a primary care physician survey from 25 countries. Scandinavian Journal of Primary Health Care, 2020, 38, 253-264.	1.5	9
85	A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years. International Psychogeriatrics, 2014, 26, 1493-1500.	1.0	8
86	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	3.6	8
87	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	3.9	8
88	Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application. BMJ Open Respiratory Research, 2019, 6, e000370.	3.0	7
89	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	1.4	7
90	Biomarker testing in MCI patientsâ€”deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	6.2	6

#	Article	IF	Citations
91	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 19853.	3.3	6
92	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.8	6
93	Reply: Do we still need positron emission tomography for early Alzheimerâ€™s disease diagnosis?. Brain, 2016, 139, e61-e61.	7.6	5
94	Coping Styles among People with Parkinsonâ€™s Disease: A Three-Year Follow-Up Study. Behavioral Sciences (Basel, Switzerland), 2020, 10, 190.	2.1	5
95	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new diseaseâ€modifying treatmentsâ€”EQâ€5D data from the Swedish BioFINDER study. Alzheimer's and Dementia, 2021, 17, 1832-1842.	0.8	5
96	Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS). Journal of Pain and Symptom Management, 2020, 60, 346-354.e2.	1.2	4
97	Astrocytic function is associated with both amyloid-Î² and tau pathology in non-dementedAPOE Ïµ4carriers. Brain Communications, 2022, 4, .	3.3	4
98	Prediction of future Alzheimerâ€™s disease dementia using plasma phosphoâ€tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.8	2
99	O1â€07â€01: Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, P140.	0.8	1
100	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA AÎ² BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670.	0.8	1
101	Spatial Distribution of Tau and Î²-Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes. Neurology, 2021, 96, 191-192.	1.1	1
102	Connecting Cohorts to Diminish Alzheimerâ€™s Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	2.6	1
103	Plasma glial fibrillary acidic protein is an early and specific marker of amyloidâ€Î² pathology in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
104	Associations between longitudinal neuropsychiatric symptoms and biomarkers of betaâ€amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.8	1
105	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Alzheimer's and Dementia, 2021, 17, .	0.8	1
106	P2-290: BIOMARKERS FOR IDENTIFYING NEURODEGENERATIVE DISORDERS EARLY AND RELIABLY (BIOFINDER): METHODOLOGY AND PRELIMINARY RESULTS OF A NEW LARGE PROSPECTIVE COHORT STUDY. , 2014, 10, P583-P584.		0
107	O2â€08â€06: CSF Analysis Detects Cerebral Bâ€Amyloid Accumulation Earlier than Amyloid Pet. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
108	[P3â€“284]: THE MONTREAL COGNITIVE ASSESSMENT: NORMATIVE DATA FROM A LARGE SWEDISH POPULATIONâ€BASED COHORT. Alzheimer's and Dementia, 2017, 13, P1051.	0.8	0

#	Article	IF	Citations
109	[O2â€“01â€“02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSSâ€VALIDATED METHOD THAT PREDICTS CEREBRAL Î²â€AMYLOIDOSIS. Alzheimer's and Dementia, 2017, 13, P548.	0.8	0
110	P3â€492: THE MISINTERPRETED AGE EFFECT ON COGNITIVE TEST RESULTS: A PRESENTATION OF TEST NORMS FROM PERSONS WITHOUT UNDERLYING PATHOLOGIES. Alzheimer's and Dementia, 2018, 14, P1310.	0.8	0
111	P4â€078: CONCORDEâ€AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1465.	0.8	0
112	O3â€14â€05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1061.	0.8	0
113	DTâ€01â€06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS. Alzheimer's and Dementia, 2018, 14, P1667.	0.8	0
114	P1â€430: EFFECTS OF APOE Îµ4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.8	0
115	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.8	0
116	F1â€04â€01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P206.	0.8	0
117	P1â€373: Î²ETAâ€AMYLOID AND WHITE MATTER LESIONS ARE INDEPENDENTLY ASSOCIATED WITH HIPPOCAMPAL ATROPHY AND REDUCED CORTICAL TEMPORAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P439.	0.8	0
118	O3â€04â€01: ASSOCIATIONS BETWEEN TAU, AÎ² AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1018.	0.8	0
119	ICâ€Pâ€036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.8	0
120	O2â€09â€01: CSF, PLASMA AND MRI BIOMARKER TRAJECTORIES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P641.	0.8	0
121	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [¹⁸F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.8	0
122	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that are impacted by APOE Îµ4, sex and age but not pathology. Alzheimer's and Dementia, 2020, 16, e040745.	0.8	0
123	Genomeâ€wide polygenic risk scores for identification of gene therapeutic target. Alzheimer's and Dementia, 2020, 16, e040903.	0.8	0
124	Health utility in preclinical and prodromal AD compared to controls: EQ5D data from the Swedish Biofinder Study. Alzheimer's and Dementia, 2020, 16, e041032.	0.8	0
125	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.8	0
126	Ability of tauâ€PET, phosphoâ€tau217, NfL and cortical thickness to predict shortâ€term cognitive decline in early symptomatic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	Citations
127	Unravelling drivers of ageâ€•and betaâ€amyloidâ€related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
128	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. Alzheimer's and Dementia, 2021, 17, .	0.8	0
129	Tau and synaptic biomarkers but not amyloidâ€Î² are associated with cerebral perfusion in the Alzheimerâ€™s disease spectrum. Alzheimer's and Dementia, 2021, 17, .	0.8	0
130	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
131	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
132	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid Pâ€tau181, Pâ€tau217 and Pâ€tau231 assays. Alzheimer's and Dementia, 2021, 17, .	0.8	0
133	Amyloidâ€Î² accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
134	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. Alzheimer's and Dementia, 2021, 17, .	0.8	0
135	The association between diet in midâ€life and dementia incidence over a 20â€year period. Alzheimer's and Dementia, 2021, 17, .	0.8	0
136	Potential drivers of ageâ€•and betaâ€amyloidâ€related neurodegeneration in early and late Alzheimerâ€™s Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
137	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053556.	0.8	0